Plant Name: Acorus gramineus
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GRM1; GABBR1; GRM3; GRM2; GRM8; GRM4; GRM5; | |
| TSHR; | |
| PTAFR; FFAR4; FFAR1; ADORA3; | |
| ACHE; | |
| RECQL; BLM; PKM; HSD17B10; HPGD; ALOX15; APEX1; POLB; | |
| GRIA4; GRIA2; GRIK3; GRIK5; GRIK1; GRIK2; | |
| GABRR1; | |
| MAPK1; PIM1; CSNK2A1; | |
| CA2; | |
| PPARA; PPARD; PPARG; | |
| ESR2; ESR1; | |
| HMGCR; | |
| ELANE; | |
| TLR2; | |
| HIF1A; TP53; | |
| KMT2A; | |
| SLC6A1; SLC1A1; SLC6A11; | |
| LMNA; FABP5; FABP2; FABP4; MCL1; MAPT; FABP3; | |
| L3MBTL1; SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| GABA-A receptor | GABRR1 | GABA receptor rho-1 subunit | P24046 | CHEMBL3561 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Ionotropic glutamate receptor | GRIA4 | Glutamate receptor ionotropic, AMPA 4 | P48058 | CHEMBL3190 |
| Ionotropic glutamate receptor | GRIA2 | Glutamate receptor ionotropic, AMPA 2 | P42262 | CHEMBL4016 |
| Ionotropic glutamate receptor | GRIK3 | Glutamate receptor ionotropic kainate 3 | Q13003 | CHEMBL3684 |
| Ionotropic glutamate receptor | GRIK5 | Glutamate receptor ionotropic kainate 5 | Q16478 | CHEMBL2675 |
| Ionotropic glutamate receptor | GRIK1 | Glutamate receptor ionotropic kainate 1 | P39086 | CHEMBL1918 |
| Ionotropic glutamate receptor | GRIK2 | Glutamate receptor ionotropic kainate 2 | Q13002 | CHEMBL3683 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Oxidoreductase | HMGCR | HMG-CoA reductase | P04035 | CHEMBL402 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Serine protease | ELANE | Leukocyte elastase | P08246 | CHEMBL248 |
| SLC superfamily of solute carriers | SLC6A1 | GABA transporter 1 | P30531 | CHEMBL1903 |
| SLC superfamily of solute carriers | SLC1A1 | Excitatory amino acid transporter 3 | P43005 | CHEMBL2721 |
| SLC superfamily of solute carriers | SLC6A11 | GABA transporter 3 | P48066 | CHEMBL5208 |
| Small molecule receptor (family A GPCR) | PTAFR | Platelet activating factor receptor | P25105 | CHEMBL250 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family C GPCR) | GRM1 | Metabotropic glutamate receptor 1 | Q13255 | CHEMBL3772 |
| Small molecule receptor (family C GPCR) | GABBR1 | GABA-B receptor 1 | Q9UBS5 | CHEMBL2064 |
| Small molecule receptor (family C GPCR) | GRM3 | Metabotropic glutamate receptor 3 | Q14832 | CHEMBL2888 |
| Small molecule receptor (family C GPCR) | GRM2 | Metabotropic glutamate receptor 2 | Q14416 | CHEMBL5137 |
| Small molecule receptor (family C GPCR) | GRM8 | Metabotropic glutamate receptor 8 | O00222 | CHEMBL3228 |
| Small molecule receptor (family C GPCR) | GRM4 | Metabotropic glutamate receptor 4 | Q14833 | CHEMBL2736 |
| Small molecule receptor (family C GPCR) | GRM5 | Metabotropic glutamate receptor 5 | P41594 | CHEMBL3227 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MCL1 | Induced myeloid leukemia cell differentiation protein Mcl-1 | Q07820 | CHEMBL4361 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | Unclassified; | GO:0004872; receptor activity | 1.382E-13 | 2.695E-10 | ADORA3, ESR1, ESR2, FFAR1, FFAR4, GABBR1, GABRR1, GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8, HPGD, PPARA, PPARD, PPARG, PTAFR, TLR2, TSHR |
| CC | GO:0044456; synapse part | GO:0042734; presynaptic membrane | 2.567E-13 | 3.727E-10 | GABBR1, GRIK2, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8 |
| MF | GO:0005215; transporter activity | GO:0005234; extracellularly glutamate-gated ion channel activity | 1.827E-11 | 1.591E-08 | GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5 |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 6.859E-11 | 4.978E-08 | ADORA3, FFAR1, FFAR4, GABBR1, GABRR1, GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8, HPGD, PPARG, PTAFR, TSHR |
| BP | GO:0009987; cellular process | GO:0035235; ionotropic glutamate receptor signaling pathway | 1.524E-10 | 1.006E-07 | GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5 |
| MF | GO:0005215; transporter activity | GO:0015277; kainate selective glutamate receptor activity | 4.195E-10 | 2.687E-07 | GRIK1, GRIK2, GRIK3, GRIK5 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.256E-09 | 6.414E-07 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| CC | GO:0044456; synapse part | GO:0045211; postsynaptic membrane | 1.704E-08 | 5.890E-06 | GABBR1, GABRR1, GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5, GRM3 |
| CC | GO:0044464; cell part | GO:0042995; cell projection | 1.973E-08 | 6.610E-06 | CA2, GABBR1, GRIA2, GRIA4, GRIK3, GRIK5, GRM1, GRM2, GRM3, GRM5, HIF1A, MAPK1, MAPT, PKM, SLC6A1, SLC6A11, SMN1, SMN2, TLR2 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 4.086E-08 | 1.255E-05 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0023052; signaling | GO:0060079; excitatory postsynaptic potential | 7.158E-08 | 2.028E-05 | GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.137E-07 | 2.983E-05 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 2.526E-07 | 5.914E-05 | ACHE, BLM, CSNK2A1, ESR1, ESR2, GRIK2, GRIK5, HMGCR, HPGD, KMT2A, L3MBTL1, MAPK1, MAPT, MCL1, PKM, PPARG, SMN1, SMN2, TP53 |
| BP | GO:0050896; response to stimulus | GO:0010038; response to metal ion | 5.760E-07 | 1.140E-04 | ALOX15, CA2, CYP1A2, FABP4, HIF1A, KMT2A, MAPK1, SLC6A1, TP53 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.013E-06 | 1.823E-04 | FABP2, FABP3, FABP4, FABP5 |
| CC | GO:0044464; cell part | GO:0043204; perikaryon | 1.505E-06 | 2.559E-04 | GRIK2, GRIK3, GRIK5, MAPK1, SMN1, SMN2 |
| CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 2.033E-06 | 3.303E-04 | GRIK2, GRIK3, HIF1A, MAPK1, MAPT |
| BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 2.362E-06 | 3.700E-04 | BLM, RECQL, TP53 |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 3.367E-06 | 4.887E-04 | CA2, GRM5, PTAFR |
| BP | GO:0007610; behavior | GO:0007612; learning | 3.996E-06 | 5.724E-04 | GRM5, HIF1A, HMGCR, KMT2A, SLC6A1, TLR2 |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 4.906E-06 | 6.805E-04 | FABP3, FFAR1, PPARG, PTAFR, TLR2 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 6.145E-06 | 8.260E-04 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0080134; regulation of response to stress | 6.789E-06 | 8.960E-04 | ELANE, ESR1, FABP4, FFAR4, GRIK2, HIF1A, HMGCR, LMNA, MAPK1, MAPT, MCL1, PPARA, PPARD, PPARG, TLR2, TP53 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 9.488E-06 | 1.188E-03 | APEX1, POLB |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 9.488E-06 | 1.188E-03 | ESR1, ESR2 |
| MF | GO:0060089; molecular transducer activity | GO:0001641; group II metabotropic glutamate receptor activity | 9.488E-06 | 1.188E-03 | GRM2, GRM3 |
| BP | GO:0065007; biological regulation | GO:0044092; negative regulation of molecular function | 1.039E-05 | 1.287E-03 | ADORA3, CSNK2A1, CYP2D6, ESR1, FABP4, GABBR1, GRM2, GRM3, HMGCR, MAPT, PIM1, PPARA, PPARG, TP53 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.113E-05 | 1.363E-03 | CYP1A2, CYP2C9, CYP2D6, CYP3A4, ESR1, HMGCR, PPARD |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.139E-05 | 1.363E-03 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0043525; positive regulation of neuron apoptotic process | 1.478E-05 | 1.667E-03 | GRIK2, GRIK5, MCL1, TP53 |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 1.694E-05 | 1.844E-03 | ESR1, ESR2, PIM1, PPARA, PPARD, PPARG |
| MF | GO:0005488; binding | GO:0001046; core promoter sequence-specific DNA binding | 2.538E-05 | 2.594E-03 | ESR1, ESR2, KMT2A, PPARG, TP53 |
| BP | Unclassified; | GO:0099566; regulation of postsynaptic cytosolic calcium ion concentration | 2.841E-05 | 2.799E-03 | GRM1, GRM5 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 2.841E-05 | 2.799E-03 | CYP2D6, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0099583; neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentration | 2.841E-05 | 2.799E-03 | GRM1, GRM5 |
| CC | GO:0032991; macromolecular complex | GO:0032983; kainate selective glutamate receptor complex | 2.841E-05 | 2.799E-03 | GRIK2, GRIK5 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 2.883E-05 | 2.828E-03 | ELANE, FFAR4, PPARA, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 3.642E-05 | 3.389E-03 | POLB, PPARG, TP53 |
| BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 4.475E-05 | 4.060E-03 | APEX1, GRM5, PKM, PPARG, TP53, TSHR |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.828E-05 | 4.326E-03 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 5.189E-05 | 4.574E-03 | ESR1, ESR2, PPARA, PPARD, PPARG |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 5.570E-05 | 4.851E-03 | FABP3, PPARA, PPARD, PPARG |
| MF | GO:0005488; binding | GO:0003684; damaged DNA binding | 5.570E-05 | 4.851E-03 | APEX1, BLM, POLB, TP53 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 5.670E-05 | 4.861E-03 | ESR1, ESR2 |
| MF | GO:0005215; transporter activity | GO:0005332; gamma-aminobutyric acid:sodium symporter activity | 5.670E-05 | 4.861E-03 | SLC6A1, SLC6A11 |
| MF | GO:0005215; transporter activity | GO:0004971; AMPA glutamate receptor activity | 5.670E-05 | 4.861E-03 | GRIA2, GRIA4 |
| BP | GO:0065007; biological regulation | GO:0030003; cellular cation homeostasis | 5.911E-05 | 5.048E-03 | CA2, ELANE, ESR1, GRIK2, GRM1, GRM5, HIF1A, MAPK1, TP53 |
| BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 6.242E-05 | 5.268E-03 | HIF1A, PPARD, TP53 |
| CC | GO:0044464; cell part | GO:0032839; dendrite cytoplasm | 6.242E-05 | 5.268E-03 | GRIK2, GRIK3, MAPK1 |
| BP | GO:0050896; response to stimulus | GO:0032868; response to insulin | 7.135E-05 | 5.863E-03 | FABP3, PKM, PPARA, PPARG, TLR2 |
| MF | GO:0005215; transporter activity | GO:0008381; mechanosensitive ion channel activity | 7.493E-05 | 6.088E-03 | GABRR1, GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5 |
| BP | GO:0050896; response to stimulus | GO:0043627; response to estrogen | 7.800E-05 | 6.263E-03 | CA2, ESR1, MAPK1, PPARG |
| BP | GO:0040007; growth | GO:0045926; negative regulation of growth | 8.196E-05 | 6.467E-03 | ELANE, ESR2, HIF1A, PPARD, PPARG, TP53 |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 8.832E-05 | 6.869E-03 | HMGCR, MAPT, TP53 |
| BP | GO:0050896; response to stimulus | GO:0014074; response to purine-containing compound | 9.003E-05 | 6.977E-03 | APEX1, PPARG, PTAFR, SLC6A1, TP53 |
| BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 9.131E-05 | 7.050E-03 | ELANE, HMGCR, HPGD, PTAFR |
| BP | GO:0009987; cellular process | GO:0051262; protein tetramerization | 9.298E-05 | 7.057E-03 | ACHE, HMGCR, HSD17B10, PKM, TP53 |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 9.432E-05 | 7.057E-03 | PPARA, PPARG |
| MF | GO:0003824; catalytic activity | GO:0009378; four-way junction helicase activity | 9.432E-05 | 7.057E-03 | BLM, RECQL |
| MF | GO:0060089; molecular transducer activity | GO:0001875; lipopolysaccharide receptor activity | 9.432E-05 | 7.057E-03 | PTAFR, TLR2 |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 9.332E-05 | 7.057E-03 | APEX1, BLM, CSNK2A1, ESR1, ESR2, FABP5, HIF1A, HPGD, KMT2A, L3MBTL1, LMNA, MAPK1, MCL1, PIM1, POLB, PPARA, PPARD, PPARG, RECQL, SMN1, SMN2, TP53 |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 9.609E-05 | 7.166E-03 | ALOX15, PPARA, PPARD, TP53 |
| MF | GO:0005488; binding | GO:0046983; protein dimerization activity | 1.054E-04 | 7.727E-03 | ACHE, BLM, GRIK2, HIF1A, HMGCR, HPGD, KMT2A, MAPT, MCL1, PPARD, PPARG, TLR2, TP53 |
| BP | GO:0050896; response to stimulus | GO:0031663; lipopolysaccharide-mediated signaling pathway | 1.204E-04 | 8.738E-03 | MAPK1, PTAFR, TLR2 |
| BP | GO:0040011; locomotion | GO:0030334; regulation of cell migration | 1.234E-04 | 8.813E-03 | ADORA3, APEX1, ELANE, HIF1A, LMNA, MAPK1, PPARD, PPARG, PTAFR, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0001816; cytokine production | 1.287E-04 | 9.157E-03 | FABP4, HIF1A, PTAFR, TLR2 |
| BP | GO:0065007; biological regulation | GO:0007194; negative regulation of adenylate cyclase activity | 1.325E-04 | 9.280E-03 | GABBR1, GRM2, GRM3 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 1.325E-04 | 9.280E-03 | CSNK2A1, HIF1A, MAPT |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 1.385E-04 | 9.598E-03 | ESR1, ESR2, PPARA, PPARD, PPARG |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.385E-04 | 9.598E-03 | ALOX15, CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0051179; localization | GO:0010887; negative regulation of cholesterol storage | 1.412E-04 | 9.638E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0010871; negative regulation of receptor biosynthetic process | 1.412E-04 | 9.638E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 1.412E-04 | 9.638E-03 | ALOX15, HPGD |
| MF | GO:0005488; binding | GO:0050543; icosatetraenoic acid binding | 1.412E-04 | 9.638E-03 | FABP3, PPARG |
| BP | GO:0009987; cellular process | GO:0007196; adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway | 6.959E-17 | 5.051E-13 | GRIK3, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04724 | Glutamatergic synapse_Homo sapiens_hsa04724 | 2.337E-19 | 3.879E-17 | GRIA2; GRIK5; SLC1A1; GRIK3; GRIK1; GRIK2; GRM1; GRM3; GRM2; GRM5; GRM4; GRM8; MAPK1; GRIA4 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 3.524E-18 | 2.925E-16 | GRIA2; GABBR1; GRIK5; PTAFR; GRIK3; GRIK1; GRIK2; TSHR; GRM1; GRM3; GRM2; GABRR1; GRM5; GRM4; ADORA3; GRM8; GRIA4 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.422E-09 | 7.869E-08 | FABP2; FABP3; FABP4; FABP5; PPARG; PPARA; PPARD |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 2.433E-07 | 1.010E-05 | GRM3; GRM2; GRM5; GRM4; GRM8; MAPK1; GRM1 |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 5.732E-07 | 1.903E-05 | GRIA2; GABRR1; GRM5; MAPK1; GRM1; GRIA4 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.181E-05 | 2.802E-04 | GABBR1; MAPK1; ESR1; ESR2; GRM1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.643E-06 | 4.546E-05 | CYP2C9; CYP1A2; ALOX15; CYP3A4 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 2.881E-05 | 5.979E-04 | GRIA2; GABBR1; MAPK1; PPARA; TSHR; GRIA4 |
| hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 4.590E-05 | 8.085E-04 | GRIA2; GRM5; MAPK1; GRM1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 4.870E-05 | 8.085E-04 | PKM; MAPK1; TP53; HIF1A |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 5.469E-05 | 8.253E-04 | CYP2C9; CYP2D6; CYP1A2; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 6.824E-05 | 9.440E-04 | CYP2C9; CYP2D6; CYP1A2; CYP3A4 |
| hsa04727 | GABAergic synapse_Homo sapiens_hsa04727 | 1.414E-04 | 1.676E-03 | GABBR1; GABRR1; SLC6A11; SLC6A1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 3.560E-04 | 3.292E-03 | MAPK1; TP53; HIF1A; ESR1; TLR2 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 2.044E-04 | 2.262E-03 | HPGD; KMT2A; PPARG; TP53; ELANE |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.569E-04 | 3.292E-03 | CYP2C9; CYP2D6; ALOX15; MAPK1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 4.351E-04 | 3.612E-03 | MAPK1; TP53; ESR1; HIF1A |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 8.872E-05 | 1.133E-03 | MAPK1; PPARG; TP53 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 8.277E-04 | 5.974E-03 | LMNA; MAPK1; TP53; MCL1 |
| hsa05033 | Nicotine addiction_Homo sapiens_hsa05033 | 2.343E-04 | 2.431E-03 | GRIA2; GABRR1; GRIA4 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 6.693E-04 | 5.291E-03 | PIM1; MAPK1; PPARD |
| hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 7.778E-04 | 5.869E-03 | GRIA2; MAPK1; GRM1 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 4.287E-04 | 3.612E-03 | GRM3; GRIA2; GRM2 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.321E-03 | 8.437E-03 | MAPK1; ESR1; ESR2 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 9.823E-04 | 6.794E-03 | CYP2C9; CYP1A2; CYP3A4 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 3.339E-03 | 1.788E-02 | POLB; PKM; MAPK1; TP53 |
| hsa04742 | Taste transduction_Homo sapiens_hsa04742 | 1.989E-03 | 1.179E-02 | GABBR1; GRM4; GRM1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.269E-03 | 8.427E-03 | CA2; HMGCR; CYP3A4 |
| hsa04713 | Circadian entrainment_Homo sapiens_hsa04713 | 2.921E-03 | 1.616E-02 | GRIA2; MAPK1; GRIA4 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 6.712E-03 | 3.193E-02 | MAPK1; PPARG; HIF1A; TP53; PPARD |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 2.350E-03 | 1.345E-02 | GRM5; MAPK1; GRM1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.921E-03 | 1.179E-02 | CYP2C9; CYP1A2; CYP3A4 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 5.621E-03 | 2.827E-02 | ADORA3; MAPK1; TP53 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 7.464E-03 | 3.442E-02 | MAPK1; PPARA; TP53 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 7.934E-03 | 3.560E-02 | CSNK2A1; TP53; TLR2 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 8.926E-03 | 3.889E-02 | CSNK2A1; TP53; PPARD |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 9.626E-03 | 3.995E-02 | MAPK1; TP53; TLR2 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.212E-02 | 4.531E-02 | PIM1; MAPK1; TP53; MCL1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.404E-02 | 4.854E-02 | MAPK1; MAPT; HSD17B10 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.228E-02 | 4.531E-02 | FABP4; TSHR |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.066E-02 | 4.213E-02 | MAPK1; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.228E-02 | 4.531E-02 | MAPK1; TP53 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.401E-02 | 4.854E-02 | MAPK1; HIF1A |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 6.732E-03 | 3.193E-02 | MAPK1; TP53 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 9.137E-03 | 3.889E-02 | PKM; MAPK1 |
| hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 1.027E-02 | 4.157E-02 | GRIA2; TP53 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.491E-02 | 4.854E-02 | MAPK1; TP53 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.314E-02 | 4.740E-02 | CYP1A2; CYP3A4 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.491E-02 | 4.854E-02 | CYP2C9; ALOX15 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 4.402E-03 | 2.283E-02 | POLB; APEX1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.491E-02 | 4.854E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| C00-D49: Neoplasms | Myeloma | C90 | SLC6A1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ELANE; PTAFR |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | HMGCR |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | ELANE; ELANE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PTAFR |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | ELANE; HMGCR |
| NA: NA | Myocardial ischaemia-reperfusion injury | NA | ELANE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PTAFR |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Septic shock | A41.9 | ELANE; PTAFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Autism | F84.0 | GRM5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; TLR2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PPARG |
| NA: NA | GERD | NA | GRM5 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; ADORA3 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | GRIK1; GRIK1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD; HMGCR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; CYP2D6 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| A00-B99: Certain infectious and parasitic diseases | HBV infection | B16, B18.0, B18.1 | HMGCR |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Elevated CRP | E78.0 | HMGCR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| NA: NA | Edema | NA | CA2 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD; HMGCR |
| NA: NA | Dyslipidemia | NA | PPARD; HMGCR |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| H00-H59: Diseases of the eye and adnexa | Conjunctivitis | H10 | PTAFR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | GRM5; CYP2D6 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Thrombocytopenia | D69.6, P61.0 | PTAFR |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | SLC6A1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | GRM1 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HMGCR |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Fragile X syndrome | F02.3, G20, Q99.2 | GRM5 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD; ESR1; HMGCR |
| NA: NA | Hyperlipidemia | NA | HMGCR |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; TP53; MAPK1; ACHE; ESR1; ESR1; TLR2; PIM1; MCL1; ADORA3; CSNK2A1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | ELANE; ELANE; ELANE |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | PTAFR |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | PTAFR |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ELANE; ELANE |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | PTAFR |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | Multiple myeloma | C90 | HMGCR |
| J00-J99: Diseases of the respiratory system | Mucolytic | J00-J99 | ELANE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | PTAFR |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| NA: NA | Cardiovascular disease | NA | HMGCR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HMGCR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | GRM2; GRM5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| NA: NA | Acute respiratory distress syndrome | NA | ELANE; ELANE; ELANE |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | GRM2; GRM4; GRM5; ACHE; CYP3A4; GRM3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | GRM2 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GRM1; GRM2; GRM5; ACHE; ACHE; ACHE; GRM3; MAPT; PPARG; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | GRM1; GRM2; GRM3 |
| K00-K95: Diseases of the digestive system | Chemotherapy or radiotherapy-induced mucositis | K12.3, R52, G89 | HMGCR |
| G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PTAFR |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; ESR1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | GRIK1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ELANE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | GRM1; GRIK1; PTAFR; ACHE; ESR1; PKM |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | GRIA4; GRIA2; ACHE |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| H00-H59: Diseases of the eye and adnexa | Ocular allergy | H00-H59 | PTAFR |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | GRM2; GRM5; PPARD; MAPT |
| I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | PTAFR |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; HMGCR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | GRM2 |
| J00-J99: Diseases of the respiratory system | Pulmonary disease | J00-J99 | ELANE |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| J00-J99: Diseases of the respiratory system | Pulmonary emphysema | J43 | ELANE |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; TLR2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; PTAFR; MAPK1; TLR2; PKM |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | GRM1; GRIK1; GRM5 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | GRM1; GRIK1; GRM4; GRM5; ESR1 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ELANE; PTAFR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
| G00-G99: Diseases of the nervous system G00-G99 | Chronic neuropathic pain | G64, G90.0, K21, R52, G89 | GRM5; GRM5 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PPARD; FFAR1; PPARG; PPARG |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| J00-J99: Diseases of the respiratory system | Bronchiectasis | J47, Q33.4 | ELANE |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD; PPARG |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | HMGCR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | GRM2; GRM2; GRM5; GRM5; GRM3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTAFR; PPARG |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| NA: NA | Upper abdominal bloating | NA | ACHE |